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When I started my career in psychiatry,
more than 20 years ago, nobody thought
about cognitive impairment in schizophre-
nia, we thought of this disorder in terms
of hallucinations and delusions. The pre-
vailing idea was that of a “chemical imbal-
ance” somewhere in the brain that one
could correct with dopamine blockers. If
we could only keep that dopamine down,
we thought, patients with schizophrenia
could live a normal life. Comparisons with
hypertension and diabetes were ubiqui-
tous, thus my generation built “clean” and
“dirty” drugs that carpet bombed receptors
far and near monoamine tracts in the brain.
These drugs were blunt and worked on
the receptors in sledgehammer-like fash-
ion. Yet, there was a lot of optimism in
the air, we were talking recovery and cure.
The working hypothesis was something like
this: our patients accidentally fell from the
bicycle of life and bruised their knees. Our
job was to bandage those knees and help
them back on the bicycle after which they
would live happily ever after.
Fast forward to the present day: med-
ications do indeed help acute symptoma-
tology of schizophrenia, but do not make a
dent in incidence, cognitive symptoms, or
disability. This year alone 100,000 young
people will have a first episode of schizo-
phrenia and 5% of them will die by suicide.
Sustained recovery is<14% within the first
5 years following a psychotic episode. In
the past 3–4 years the new psychotropic
drugs’ pipeline became dry. There are mul-
tiple reasons for this state of affairs, but
the main one is the lack of success with
new mechanisms of action of antipsy-
chotic and antidepressant drugs as well
as lack of viable, measurable biological
markers. In terms of new drugs for our
patients, there will be few in the coming
years. I believe that we are in a stagnation
period that will probably last a decade or
more.
MEANWHILE PSYCHIATRY IS
GRADUALLY BECOMING A BRANCH OF
CLINICAL NEUROSCIENCE
Many psychiatrists do not agree with this
trajectory for our field. Just like the psy-
chiatrists of the previous generation felt
comfortable in psychoanalysis, some psy-
chiatrists today feel that they are experts
in psychopharmacology by memorizing
details about the interaction of drugs with
neurotransmitters and receptors. However,
many of the same psychiatrists, have lit-
tle real understanding or concern about
what actually might be wrong in the brains
of individuals with psychiatric disorders,
being content to describe the illness as a
“chemical dysfunction.” Moreover it is not
clear that any psychotropic drugs in use
today have anything to do with the etiol-
ogy or pathogenesis of the diseases they are
used to treat.
SO WHAT IS HAPPENING IN
PSYCHIATRY WHEN NOTHING IS
GOING ON?
Here is what is happening in the back-
ground: the pause in new drug develop-
ment is leading to the design of new, finer
tools of the trade that are gradually enlarg-
ing our understanding of brain physiology
and pathology. There is not much talk in
the media about the development of these
new tools, they are taking shape quietly,
behind the scenes in academic settings, but
they are already bearing fruit.
WHAT ARE THE NEW TOOLS?
VISUALIZING THE THOUGHTS (IN VIVO TWO
PHOTON LASER SCANNING MICROSCOPY)
The dream of neuroscientists for the past
centuries was to be able to see the brain at
work in vivo. This finally came to fruition
by the advent of two photon laser scan-
ning microscopy. This technique allows us
to peer in the brain of live mice or cul-
tured brain cells and to record ongoing
cellular processes in real time. We are learn-
ing vital information on dendritic spines of
pyramidal neurons. Dendritic spines: cor-
tical pyramidal neurons, express tens of
thousands of small protuberances on their
dendritic trees. These dynamic structures
receive excitatory information from other
neurons, and play a significant role in cog-
nition. It is believed that changes in spine
number or morphology precede the cog-
nitive cascade in many neuropsychiatric
disorders.
Fruits
Patients with schizophrenia, for example,
present with decrease in basal dendrites
and spines in layers three and five, espe-
cially in area nine of the brain. Techniques
to measure dendritic spine density are
emerging as new biological markers of the
disease (1). Novel neuroprotective com-
pounds and techniques (such as electri-
cal stimulation) seem to increase dendrites
and spines, especially in the hippocampus.
OPTOGENETICS
Optogenetics is an in vivo technique that
came about by combining genetics and
optics to control events within brain cells.
This is how it works: genes coding for
light sensitive or fluorescent proteins are
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inserted into the mouse DNA. Part of the
rodent’s skull is replaced by a transpar-
ent material, creating a window through
which the brain is visualized. This tech-
nique allows scientists not only to see the
light sensitive proteins at work in a moving
mouse, but also to switch on and off (via
light) various neural circuits.
Fruits
Using optogenetics, scientists were able
to manipulate EEG gamma oscillations
(~40 Hz) thought to be crucial for cog-
nition in schizophrenia. Optogenetics has
also been combined with fMRI. Optoge-
netic functional magnetic resonance imag-
ing (ofMRI) is a novel approach that com-
bines optogenetic control of neural circuits
with high-field functional MRI, creating a
powerful tool that can monitor and influ-
ence neural activity arising from specific
circuits in any area of interest (2).
“I CANNOT SEE A STRING, BUT I CAN SEE A
CABLE” (WHITE MATTER TRACTOGRAPHY)
We can see individual neurons (in cultures
or brain) by microscopy only, they cannot
be seen in real time in vivo in the brain.
Why not? The best MRI machines now-
a-days have a resolution of about 1 mm.
The problem is that 1 mm of brain tissue
contains about 1,000 neurons.
What about axons? The good news is
that axons travel together forming thick
cables. Large cables, like corpus callosum,
can be seen by naked eye. Thinner ones
(more than 1 mm) can be picked by MRI
and thus can be seen in vivo in real
time. That is how white matter tractog-
raphy originated. The human connectome
project is a very ambitious plan of map-
ping the entire white matter (“cables” that
connect brain regions) in healthy and dis-
eased brains. Wernicke (3) was the first
to posit that abnormal connections among
brain regions may play a critical role in the
etiology of schizophrenia.
Fruits
It is currently believed that schizophrenia
is a neurodevelopmental brain dysconnec-
tion syndrome, involving abnormal inter-
actions between widespread brain net-
works. Accumulating evidence from a
growing number of neuroimaging stud-
ies have begun to identify heritable bio-
markers of this complex disorder. Cur-
rent studies demonstrate both reduced and
enhanced connectivity among several brain
areas, including dorso-lateral prefrontal
cortex (DLPF) with the temporal lobe,
parietal lobe,hippocampal formation, thal-
amus and cerebellum, cingulate cortex, and
also limbic regions (particularly amygdala-
frontal connections) (4). There are novel
rehabilitation techniques that seem to help
the brain“rewire”to a certain extent during
adult life.
SCHIZOPHRENIA IN A PETRI DISH (CULTURED
NEURONS)
Neuropsychiatric disorders can be studied
more effectively thanks to a new method
for obtaining mature neurons from repro-
gramed skin cells. Researchers can take skin
cells from living patients and convert them
into neurons or astrocytes that mimic the
activity of the patient’s own brain cells.
These studies have demonstrated the col-
laborative role between neurons and astro-
cytes in human cognition. Astrocytes par-
ticipate in glutamatergic tripartite synapses
that support cognitive functions, such as
learning, perception, conscious integra-
tion, memory formation, and retrieval.
Fruits
In the past few years the classical view of
astrocytes as a simple supportive cell for
neurons, has been replaced by a new vision
in which glial cells are active elements of the
brain. For example, neurons grown in vitro
along with astrocytes differentiate more
rapidly and form many more synapses than
neurons grown alone. This raises the possi-
bility that astrocytes may be as important,
or even more important than neurons, not
only during brain development, but also in
its day to day function and cognition. Tar-
geting astrocyte receptors and pathology is
rapidly becoming a novel area of interest in
cognitive disorders (5).
GAZING INTO THE CRYSTAL BRAIN (CLARITY)
Another tool discovered recently is called
CLARITY. CLARITY is an acronym, for
Clear Lipid-exchanged Anatomically Rigid
Imaging/immunostaining-compatible Tis-
sue hydrogel. By replacing the brain’s fat
with a clear gel, CLARITY turns the opaque
and impenetrable brain into a transparent
and permeable structure. This postmortem
technique allows us to look into the human
brain like into a crystal ball and identify
cells and tracts with utmost precision.
Fruits
This postmortem technique is complemen-
tary to the in vivo human connectome
project. It can microscopically zoom in and
provide details that fMRI may miss because
of limited resolution (6).
YOU ARE NEVER ALONE, YOU ALWAYS HAVE
YOUR GERMS (THE HUMANMICROBIOME)
The microbial world of our bodies was
recently mapped by a consortium of sci-
entists. The results show that our bodies
are complex ecosystems in which human
cells represent only 10% of the population.
These results have altered how we think
about what it means to be human.
Fruits
How our microbial world influence the
development of brain and behavior will
be one of the great frontiers of clinical
neuroscience in the next decade (7).
IF IT IS NOT NATURE IT MUST BENURTURE
(MAPPING THE EPIGENOME)
All the cells of our body have exactly the
same genes, yet a skin cell, for example,
is very different from a muscle fiber or
a neuron. Why? Because only the perti-
nent genes in each cell are allowed to be
expressed, while the others are silenced by
the epigenome. Epigenetics refers to the
study of stable, often heritable, changes
that influence gene expression that are
not mediated by DNA sequence. Multi-
ple disease processes, including cancer, are
now well known to be associated with
characteristic alterations in the epigenome,
such as the patterns of chromatin, DNA
methylation, and gene expression. The
recently launched NIH Roadmap Epige-
nomics Mapping Consortium, provides
a public resource of human epigenomic
data for use in basic biology and disease-
oriented research. This project is com-
plementary to ENCODE (ENCyclopedia
of DNA Elements) launched in Septem-
ber 2003, to identify the human genome
sequence.
Fruits
Until recently, research has primarily
focused around the role of genetic fac-
tors in schizophrenia, but other variables,
including the environment, were found to
be as important in the onset of the disease.
For example, genetic variation alone can-
not explain why identical twins often differ,
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with one twin developing schizophrenia,
and the other being free of the condition. A
promoter on chromosome 17q25.1 called
ST6GALNAC1 was found to differ in iden-
tical twins discordant for schizophrenia. In
the future this new knowledge may be used
to develop a blood test to diagnose patients
with schizophrenia (8).
WHAT DOES THE BRAIN DOWHEN IT DOES
NOTHING? (LOW FREQUENCY OSCILLATIONS
AND DMN)
Recent functional magnetic resonance
imaging studies have identified structured
patterns of slow neuronal oscillations in
the resting human brain (0.001–0.1 Hz). It
was called default mode network (DMN)
and it refers to a group of cortical areas
that are most active in the resting state
and decreases its activity during the per-
formance of a task. This brain network
transcends levels of consciousness, being
present during anesthesia, sleep, or coma
raising speculations about the origin of
what we call self-awareness or conscious-
ness. The DMN was found to differ in
schizophrenia patients with poor insight
compared to those with good insight (9).
Poor insight is believed to reflect decreased
connectivity in the DMN.
Fruits
A new methodology to enhance brain con-
nectivity (help the adult brain re-“wire”)
in schizophrenia was recently described.
It is called fMRI-brain-computer inter-
faces (fMRI-BCI). This novel therapeu-
tic technique allows subjects to achieve
self-regulation of various brain regions by
getting feed-back via real time fMRI (10).
DE NOVO MUTATIONS
Given the significantly reduced fertility of
individuals with schizophrenia, why has the
prevalence of this disease remained sta-
ble over time? Several recent studies have
shown that newly arising (de novo) muta-
tions contribute to the genetics of schiz-
ophrenia. The strongest evidence to date
for the association between schizophrenia
and de novo mutation comes from stud-
ies of copy number variation (CNV). What
are CNVs? CNVs are microdeletions or
microduplications of one or more sections
of the DNA on a specific chromosome.
Recent data robustly confirm the asso-
ciation of schizophrenia with 1q21.1,
15q13.3, and 22q11.21 deletions, 16p11.2
duplications, and exonic NRXN1 deletions.
However the strongest association with this
disease is a deletion in chromosome 3q29
that was previously described in a mild-
moderate mental retardation syndrome,
autism spectrum disorders, and epilepsy.
Fruits
A small CNVat 22q13.31 on schizophre-
nia affects the gray matter concentration
(GMC) in the frontal cortex, demonstrat-
ing that CNVs not only have the potential
of influencing schizophrenia risk, but also
altering GMC in specific brain regions (11).
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